CAMP

THE SCIENCE AND TECHNOLOGY TO TRANSLATE ATMPs FROM LAB TO CLINIC

CAMP is a Vinnova funded project focussing on the science and technology required to translate ATMPs from lab to clinic, including bioprocess development, GMP production and logistics. CAMP drives collaboration between researchers, GMP competent resources, industry and hospitals. CAMP gathers all of the university hospitals in Sweden, all research institutes with significant activity in ATMP and both large and small companies active in the ATMP field.

Coordinator: Umeå universitet

Partners: ACOUSORT, Akademiska Sjukhuset, Amniotics, AstraZeneca, Celgene (a BMS company), Cellastra Inc., CELLINK, CELLSEED, Cytiva, Göteborgs Universitet, Idogen, IsletOne, Karolinska Institutet, Karolinska Universitetssjukhuset, Key2Compliance, KTH, Linköping University, LIF, MAGic Bioprocessing, MEDICON VILLAGE, NEOGAP Therapeutics, NextCell Pharma, NORICON, NorthX Biologics, Novartis, PFIZER, Region Örebro, Region Skåne, Region Västerbotten, Region Östergötland, RISE, Svenska Vaccinfabriken Produktion, TAKARA BIO EUROPE, TATAA Biocenter, Uppsala University Hospital, VÄSTRA GÖTALANDSREGION, VERIGRAFT, VivaBioCell S.p.A., Xintela, XNK Therapeutics, YSDS

Workpackages

  • Process Development
  • Infrastructure for GMP manufacturing
  • Quality control, shelf-life and logistics

For a list of projects see here

Contact: Jukka Lausmaa – Centre Director

Paul Kingham – Centre Coordinator

The overall long term objective is to develop general cell processing development principles and methods for an effective transfer from preclinical to clinical, GMP-compatible production.

Related content

Become a partner

Help us to revolutionise healthcare! Build a partnership with our organisation.

Sign up to our newsletter

The ATMP newsletter is a quarterly newsletter updating on Swedish ATMP developments.